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At first glance, the molecular and cellular mechanisms 
governing aging and cancer appear to be completely 
distinct, even opposite in terms of their phenotypes. On 
one hand, aging represents a slow, often degenerative 
decline in cellular functions, while cancer cells are 
thought be “hyper-functional”. But are they really that 
opposite? It is no secret that aging increases one’s 
susceptibility to many diseases, including cancer. In 
fact, as aging populations throughout the world 
increase, there has been an unprecedented rise in cancer 
incidence and mortality. More than 50 percent of all 
cancers are diagnosed in patients 65 years or older [1]. 
There is now more than ever an urgent need to better 
understand the interplay between aging and cancer. This 
knowledge will undoubtedly improve clinical 
management of geriatric cancer patients. Here, we 
discuss some intriguing factors linking these two 
seemingly paradoxical conditions.   
There are several age-related epigenetic defects 
reminiscent of those commonly observed in cancer, 
suggesting a potential link between age-dependent 
biological changes and the concomitant increased 
cancer risk observed in the aged population. These 
include several global changes in the chromatin, altered 
gene expression, and overall genomic instability. For 
instance, certain site-specific hypermethylation events 
at promoters of genes involved in aging have also been 
reported as occurring during cancer. Notably, these 
include hypermethylation patterns at tumor-suppressor 
genes, such as suppressor of cytokine signaling 1 
(SOCS1), hypermethylated in cancer 1 (HIC1), 
adenomatosis polyposis coli (APC), and a set of genes 
collectively termed the Polycomb group protein (PcG) 
target genes [2]. The resulting epigenetic silencing of 
these genes typically precedes many of the 
transformation events that give rise to cancer, further 
underscoring the idea that elucidating changes in the 
DNA methylome during aging may provide a powerful 
platform for better understanding the factors 
contributing to tumorigenesis.  
Aged-related changes in genomic imprinting constitute 
another aspect of epigenetic alterations in cancer. For 
instance, loss of imprinting (LOI) for the insulin growth 
factor 2 (IGF2) has been shown to be important in 
cancer progression. Fu et al demonstrated that increased 
IGF2 expression occurred as a result of selective LOI 
for IGF2 in the prostate of men during aging which  was  








shown to be more extensive in men with age-associated 
prostate cancer [3].  
In addition to epigenetic changes, senescence also 
stands out as an important link between aging and 
cancer. First described by Hayflick and Moorhead in 
1961 [4], age-associated senescence denotes a cell-
autonomous state in which cells undergo irreversible 
cell cycle arrest marked by certain “Hayflick factors”, 
such as telomere loss, genomic instability, oxidative 
stress, and the accumulation of DNA damage [4]. 
Interestingly, many of these factors are intrinsic 
components of common age-related types of cancer, 
including breast, skin, and lung cancers [5].  
Although senescence has been recognized to be a tumor 
suppressor mechanism due to its strong antiproliferative 
power, ironically, emerging evidence suggests that as 
the number of senescent cells increase with age, a more 
permissive tissue microenvironment develops which 
may, contribute significantly both to the initiation and 
progression of cancer. This is facilitated by a process 
that develops in advanced senescent cells known as the 
senescence-associated secretory phenotype (SASP) [6]. 
SASP is characterized by senescence-associated 
changes in which robust levels of cytokines, chemo-
kines, and growth factors secreted into the surrounding 
microenvironment, acting on premalignant and tumor 
cells in a paracrine fashion, promoting a highly 
inflammatory state that enhances the invasive 
capabilities of these cells. Not surprisingly, this 
parallels a major pervasive feature of aging, i.e. a 
persistent state of chronic and systemic inflammation, 
which has been shown to exponentially increase the risk 
of cancer development. SASP is largely initiated by 
interleukin 1 alpha and beta (IL-1α and β), which serve 
as potent activators of important cancer signals, 
including the nuclear factor-κB (NF-κB) and p38 
mitogen-activated protein kinase (p38MAPK) 
pathways. These pathways along with SASP can then 
serve to further activate a wide array of critical target 
gene products including those involved in epithelial-to-
mesenchyme transition (EMT) (eg. Metallomatrix 
proteins (MMPs), and metastasis (eg. MMPs, IL-6) of 
cancer cells [6]. 
Therapeutic strategies for treating elderly cancer 
patients are influenced by several complicating factors, 
many of which stem from natural frailty and other age-
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population.  For instance, severity of age-related 
ailments, impaired renal/hepatic function, and altered 
metabolism of therapeutics are just a few factors that 
influence tolerance for the toxicity associated with more 
aggressive chemotherapeutic and radiation regimens 
[5]. Furthermore, this is compounded by an alarming 
underrepresentation of older patients in randomized 
cancer-related trials, leading to a paucity of evidence-
based benefit of newer, more effective drugs in older 
cancer patients [7].  By developing more appropriate 
clinical trials dedicated to older individuals, the hope is 
that further elucidation of the interplay between aging 
and cancer will give clinicians much-needed improve-
ment in risk assessment and therapeutic intervention 
strategies to improve survival and quality of life for 
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Figure 1. Mechanisms of  interplay  between  aging  and  cancer.
 During  normal  aging,  accumulation  of  damaged  DNA,  telomere
loss,  mutations  and  subsequent  oxidative  stress‐dependent
changes,  the  so‐called  “Hayflick  factors”  lead  to overall  genomic
instability.   Meanwhile,  the  increasing  abundance  of  aberrant
epigenetic  changes  such  as  DNA  hypermethylation  and  loss  of
imprinting  (LOI)  can  also  significantly  contribute  to  genomic
instability.  Yet  another  complication  arises  as  these  advanced
senescent  cells  develop  the  senescence‐associated  secretory
phenotype  (SASP),  which  is  accompanied  by  robust  cytokines
secretion  that can act on premalignant cells  to promote a highly
inflammatory  tissue microenvironment. SASP  itself  is  initiated by
certain  pro‐inflammatory  cytokines  which  serve  as  potent
activators of important inflammatory signals, including the nuclear
factor‐κB  (NF‐κB)  and  p38  mitogen‐activated  protein  kinase
(p38MAPK)  pathways.  These  pathways,  once  activated,  can  also
establish  a  feed‐forward  loop  via  the  transcription  of  cytokine
target  genes  that  in  turn  activate  SASP.  Overall,  this  results  in
activation  of  an  epithelial‐to‐mesenchyme  transition  (EMT)  and
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